On November 8, 2017 Kymab reported that its team will present data at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 32nd Annual Meeting on its novel anti-ICOS antibody KY1044, the lead candidate in its immuno-oncology pipeline, which shows strong potential for inhibiting tumour growth (Press release, Kymab, NOV 8, 2017, View Source [SID1234537008]). The poster is available online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kymab’s data, which is based on non-human tumour models, suggests that KY1044 strongly inhibits tumour growth, including complete remissions, in a number of cancer models, both as a monotherapy and acting synergistically in combination with checkpoint inhibitors such as anti-PD-L1.
"We are excited to unveil KY1044, the lead development product in our growing immuno-oncology franchise, where we are focusing on enabling the patient’s own immune system to boost its intrinsic ability to eradicate tumours," says Dr David Chiswell, CEO of Kymab.
"We believe that KY1044 has considerable potential and will provide patient benefits in a significant number of cancer indications."
KY1044 is a fully human antibody that allows the immune system to better recognise and kill tumours.
KY1044 has a dual mode of action: stimulating immune cells which are fighting the tumour, while also killing a type of cell known as T regulatory cells (Tregs). Tregs are often found in tumours and inhibit the immune response and prevent or slow the activity of anti-tumour T-cells.
Intratumoural Tregs express a high level of ICOS on their surface. Removing these cells using KY1044 allows the immune system to work more effectively at killing cancer cells.
Kymab plans to file an investigational new drug application for KY1044 in late 2018 and commence clinical trials in 2019. KY1044 will be evaluated in cancer patients both as a monotherapy and in combination with other immunotherapies.
The SITC (Free SITC Whitepaper) meeting is being held on 8-12 November 2017 at the Gaylord National Hotel & Convention Center, in Maryland, USA. The Kymab poster will be presented on Saturday, 11 November, 2017 at 12.30 to 14.00 and 18.00 to 20.00. Please see below for more information.
Notes to Editors
Issued Cambridge, UK, 8 November 2017
Read the PDF version of the issued Press Release
About Kymab’s SITC (Free SITC Whitepaper) Poster
Title: KY1044, a novel anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy or in combination with immune checkpoint inhibitors.
Poster Number: 288
Date: Saturday, November 11, 2017
Session Time: 12.30 to 14.00 and 18.00 to 20.00
Location: Prince George’s Exhibition Hall DE, Gaylord National Hotel & Convention Center, in Maryland, USA
The Kymab poster is available at: View Source